Metabolic Surgery Diabetes Remission (MDR) Score: a New Preoperative Scoring System for Predicting Type 2 Diabetes Remission at 1 Year After Metabolic Surgery in the Singapore Multi-ethnic Asian Setting

Moh, Mei Chung; Cheng, Anton; Tan, Chun Hai; Lim, Boon Khim; Tan, Bo Chuan; Ng, Deborah; Sum, Chee Fang; Tavintharan, Subramaniam; Lim, Su Chi

doi:10.1007/s11695-020-04576-3

Cited by 7 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cohort, 74.8% and 79.4% of patients experienced complete T2DM remission at 1 year and 3 years after bariatric surgery, respectively. Consistently, a retrospective analysis of 114 individuals who underwent RYGB revealed that 47.4% achieved complete T2D remission during a mean follow-up of 12 months [ 24 ]. 1-year after surgery, we observed 74.8% complete remission and 5.7% partial remission rates.…”

Section: Discussionmentioning

confidence: 93%

Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study

et al. 2022

View full text Add to dashboard Cite

Background Several studies on various bariatric surgeries involving patients with type 2 diabetes mellitus (T2DM) showed an overall rate of remission of hyperglycemia. However, there is little known about predictive factors on remission after different types of surgeries. The aim of this study was to identify the T2DM remission rate and to determine the effects of preoperative factors characteristics of remission of type 2 diabetes in Iran. Methods We conducted a retrospective analysis of 1351 patients with T2DM operated by three different types of surgeries (Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and One Anastomosis Gastric Bypass (OAGB)). Diabetes remission was defined according to the American Diabetes Association (ADA) criteria. Binary logistic regression analyses were employed. Results A total of 1351 patients, 675 patients (50.0%) undergoing OAGB, 475 (35.2%) RYGB, and 201 (14.9%) SG. 80.6%, 84.2% of OAGB, 81.7%, 82.6% of RYGB, and 77.1%, 81.5% of SG participants were in T2DM remission after 1 and 3 years, respectively. 1- and 3-year remission were associated with preoperative age, duration of T2DM, FBS and HbA1c, BMI, insulin therapy, and a family history of obesity (p < 0.05). Conclusion The remission of T2DM after RYGB, SG, and OAGB surgery is dependent on various preoperative factors. Patients with younger age, shorter duration of T2DM, lower preoperative HbA1c and FBS, higher BMI, who were not on insulin therapy, and not having a family history of obesity were the best candidates to achieve a prolonged diabetes remission.

show abstract

Section: Discussionmentioning

confidence: 93%

Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Even though several scores have been proposed to predict diabetes remission after metabolic surgery [13][14][15][16][17], none are actually effective. The present study focused on the identification of the early determinants of the resolution of T2D in severely obese patients after bariatric surgery by applying a non-targeted proteomic analysis to plasma proteins.…”

Section: Introductionmentioning

confidence: 99%

Remission of Diabetes Following Bariatric Surgery: Plasma Proteomic Profiles

Insenser

Vilarrasa

Vendrell

et al. 2021

JCM

View full text Add to dashboard Cite

Bariatric surgery restores glucose tolerance in many, but not all, severely obese subjects with type 2 diabetes (T2D). We aimed to evaluate the plasma protein profiles associated with the T2D remission after obesity surgery. We recruited seventeen women with severe obesity submitted to bariatric procedures, including six non-diabetic patients and eleven patients with T2D. After surgery, diabetes remitted in 7 of the 11 patients with T2D. Plasma protein profiles at baseline and 6 months after bariatric surgery were analyzed by two-dimensional differential gel electrophoresis (2D-DIGE) and matrix-assisted laser desorption/ionization-time-of-flight/time-of-flight coupled to mass spectrometry (MALDI-TOF/TOF MS). Remission of T2D following bariatric procedures was associated with changes in alpha-1-antichymotrypsin (SERPINA 3, p < 0.05), alpha-2-macroglobulin (A2M, p < 0.005), ceruloplasmin (CP, p < 0.05), fibrinogen beta chain (FBG, p < 0.05), fibrinogen gamma chain (FGG, p < 0.05), gelsolin (GSN, p < 0.05), prothrombin (F2, p < 0.05), and serum amyloid p-component (APCS, p < 0.05). The resolution of diabetes after bariatric surgery is associated with specific changes in the plasma proteomic profiles of proteins involved in acute-phase response, fibrinolysis, platelet degranulation, and blood coagulation, providing a pathophysiological basis for the study of their potential use as biomarkers of the surgical remission of T2D in a larger series of severely obese patients.

show abstract

“…The study population is nested within our large prospective Obesity—Metabolism & Intervention Cohort Study (OMICS), which has previously been described. 3 In brief, moderate to severely obese adults (mean body mass index [BMI] 42.6 ± 7.9 kg/m 2 ) with or without diabetes scheduled for metabolic surgery were recruited between August 2007 and May 2022 (N = 654). This retrospective study included people who underwent laparoscopic adjustable gastric banding (LAGB), Roux-en-Y gastric bypass (RYGB), or sleeve gastrectomy (SG) and had at least 1-year follow-up data post-surgery.…”

Section: Methodsmentioning

confidence: 99%

Short-term Weight Trajectory of Severely Obese Individuals With and Without Pathogenic Satiety-Regulation Melanocortin 3/4 Receptor (MC3/4R) Mutations From a Multi-ethnic Asian Large Bariatric Surgery Program

Lim

Moh

Pandian

et al. 2023

Journal of Investigative Medicine High Impact Case Reports

Self Cite

View full text Add to dashboard Cite

The melanocortin (3 or 4) receptor (MC3/4R) is involved in regulating satiety and body weight. Therefore, pathogenic mutation in MC3/4R is associated with severe obesity, for which bariatric surgery is one of the treatment options. However, there is limited data on whether individuals with MC3/4R mutation will have differential weight response to surgery, especially among the Asian populations—the epi-center of the evolving global obesity epidemic. From our large prospective Obesity—Metabolism & Intervention Cohort Study (OMICS; N = 654, recruited between 2007 and 2022), 5 individuals with pathogenic MC3/4R mutations (“case”) were identified using candidate-genes panel next-generation sequencing (Illumina iSeq). These subjects were carefully propensity score–matched (baseline body mass index [BMI], age, sex, ethnicity, proportion with diabetes, type of bariatric surgery) in a 1:4 ratio to other controls. We performed linear mixed model analysis (for repeated measurements) to compare their longitudinal weight trajectories (percentage total weight loss, %TWL) over 12 months. The 5 cases with MC3/4R mutations were 48 ± 11 years, BMI 40.8 ± 11.2 kg/m2, 60% with diabetes, and all males. Their weight at baseline (pre-op), and 6 months and 12 months after surgery were 120 ± 38, 100 ± 31, and 101 ± 30 kg, respectively. Compared with propensity score–matched controls (N = 20), linear mixed model analysis suggested no difference in surgically induced %TWL (β coefficient = −5.8 ± 3.7, P = .13) over 12 months between the groups. Therefore, we conclude that rare pathogenic MC3/4R mutations do not significantly modify weight change (%TWL) in response to bariatric surgery.

show abstract

Metabolic Surgery Diabetes Remission (MDR) Score: a New Preoperative Scoring System for Predicting Type 2 Diabetes Remission at 1 Year After Metabolic Surgery in the Singapore Multi-ethnic Asian Setting

Cited by 7 publications

References 22 publications

Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study

Type 2 diabetes remission after Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and one anastomosis gastric bypass (OAGB): results of the longitudinal assessment of bariatric surgery study

Remission of Diabetes Following Bariatric Surgery: Plasma Proteomic Profiles

Short-term Weight Trajectory of Severely Obese Individuals With and Without Pathogenic Satiety-Regulation Melanocortin 3/4 Receptor (MC3/4R) Mutations From a Multi-ethnic Asian Large Bariatric Surgery Program

Contact Info

Product

Resources

About